Real-world Clinical Benefit Evaluation in Breast Cancer Patients With Pharmaceutical Interventions for Cancer-related Fatigue
1 other identifier
observational
261
1 country
9
Brief Summary
This retrospective study is to collect and analyze the data from medical records within the period that breast cancer patient is receiving NHI-covered CRF treatment. This study will evaluate the clinical use, fatigue improvement, and treatment satisfaction of breast cancer patients with CRF treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2021
Typical duration for all trials
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 8, 2021
CompletedFirst Submitted
Initial submission to the registry
June 13, 2022
CompletedFirst Posted
Study publicly available on registry
June 23, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 28, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedJuly 3, 2024
July 1, 2024
2.3 years
June 13, 2022
July 2, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Fatigue Improvement
through study completion, an average of 4 months
Secondary Outcomes (8)
The Level of Fatigue Clinical Global Impression-Improvement
through study completion, an average of 4 months
Physician Satisfaction Degree of Overall Clinical Evaluation
1 time, average of 4 months after baseline (at the end of study)
Patient Expectation Rating of Continuous Cancer-Related Fatigue Treatment
1 time, average of 4 months after baseline (at the end of study)
ECOG Change
through study completion, an average of 4 months
Weight Change
through study completion, an average of 4 months
- +3 more secondary outcomes
Study Arms (1)
Breast cancer patients with Cancer-related fatigue treatment
Breast cancer patients who approved to use NHI to pay for Cancer-related fatigue treatment drug
Eligibility Criteria
breast cancer patients who approved to use NHI to pay for cancer-related fatigue treatment drug
You may qualify if:
- breast cancer patients who approved to use NHI to pay for cancer-related fatigue treatment drug
You may not qualify if:
- N/A
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- National Defense Medical Center, Taiwanlead
- Taichung Veterans General Hospitalcollaborator
- E-Da Cancer Hospitalcollaborator
- Chang Gung Memorial Hospital, Taipeicollaborator
- Chang Gung Memorial Hospitalcollaborator
- Tri-Service General Hospitalcollaborator
- China Medical University Hospitalcollaborator
- Kaohsiung Medical University Chung-Ho Memorial Hospitalcollaborator
- Mackay Memorial Hospitalcollaborator
- Chang Gung Memorial Hospital, Keelungcollaborator
Study Sites (9)
E-Da Cancer Hospital
Kaohsiung City, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Chang Gung Memorial Hospital, Keelung
Keelung, Taiwan
China Medical University Hospital
Taichung, Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan
Mackay Memorial Hospital
Taipei, Taiwan
Taipei Chang Gung Memorial Hospital
Taipei, Taiwan
Tri-Service General Hospital
Taipei, Taiwan
Linkou Chang Gung Memorial Hospital
Taoyuan District, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief of Department of Oncology
Study Record Dates
First Submitted
June 13, 2022
First Posted
June 23, 2022
Study Start
September 8, 2021
Primary Completion
December 28, 2023
Study Completion
December 31, 2023
Last Updated
July 3, 2024
Record last verified: 2024-07